A UC-Davis graduate student is receiving treatment in Texas for a rare and potentially fatal malignant tumor after launching an online petition to pressure insurer Anthem Blue Cross to cover the cost of the experimental treatment. Anthem in a letter said its evaluators made an exception and that the decision "does not mean that we endorse the safety or effectiveness" of the treatment.